These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28799823)

  • 1. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.
    Yu RZ; Gunawan R; Li Z; Mittleman RS; Mahmood A; Grundy JS; Singleton W; Geary R; Wang Y
    Eur J Clin Pharmacol; 2016 Mar; 72(3):267-75. PubMed ID: 26645588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
    Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
    Rekić D; Azarov I; Knöchel J; Sokolov V; Nilsson C; Wernevik L; Han D; Rydén-Bergsten T; Ebrahimi A; Dota C; Carlsson B
    Br J Clin Pharmacol; 2022 Nov; 88(11):4839-4844. PubMed ID: 35653229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
    Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
    J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting
    Watts LM; Karwatowska-Prokopczuk E; Hurh E; Alexander VJ; Balogh K; O'Dea L; Geary RS; Tsimikas S
    Nucleic Acid Ther; 2020 Aug; 30(4):198-206. PubMed ID: 32589506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
    Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
    Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
    Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
    PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.
    Mondal SA; Assaf M; Liu L; O'Mara E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):251-8. PubMed ID: 26754679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
    Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
    Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
    Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056).
    Ufer M; Sagkriotis A; Salunke A; Ganesan S; Tisserant A; Dodman A; Voltz E; Woessner R; Jordaan P; Legangneux E
    Clin Ther; 2016 Dec; 38(12):2589-2597. PubMed ID: 27823869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.